The gap between clinical trials and the real world: Extrapolating treatment effects from younger to older adults

JAMA Internal Medicine

Volumn 174, Issue 3, 2014, Pages 397-398

  Tinetti, Mary E ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; END STAGE RENAL DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84897714560     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.13283     Document Type: Note

References (7)

1. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168(2):136-140. (Pubitemid 351185879)
2. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233-1240. (Pubitemid 46465731)
3. O'Hare AM, Hotchkiss JR, Kurella Tamura M, et al. Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults [published online January 13, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2013.13328.
4. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866. (Pubitemid 44596195)
5. Butler M, Talley KM, Burns R, et al. Values of older adults related to primary and secondary prevention. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Evidence synthesis 84. AHRQ publication 11-05154-EF-1. http://www.ncbi.nlm.nih.gov/books/NBK53769/. Accessed November 27, 2013.
6. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011;171(10):923-928.
7. Leipzig RM, Whitlock EP, Wolff TA, et al US Preventive Services Task Force Geriatric Workgroup. Reconsidering the approach to prevention recommendations for older adults. Ann Intern Med. 2010;153(12):809-814.